Regulatory Explainer

What Is a Compounded Peptide?

Pharmacy compounding is a real, long-standing practice with real rules. Here's what those rules actually require, and where peptides like BPC-157 and TB-500 stand under them today.

Last reviewed October 29, 2026 8 min read By Dave Belmonte, Founder
Compounding Section 503A FDA Regulatory
Back to Expert Insights

Quick Answer

A compounded peptide would beIt is not
Prepared by a licensed pharmacy for one patient's valid prescriptionA bulk-manufactured, mass-produced drug
Overseen by the FDA and a state pharmacy boardA "research use only" vial bought online
Legal only for a substance that meets specific 503A conditionsCurrently possible for most research peptides, including BPC-157

What Is Pharmacy Compounding?

Pharmacy compounding is the practice of a licensed pharmacist, or a physician, customizing a medication for an individual patient's specific needs. It's a long-standing part of pharmacy practice, not a workaround or a loophole. Common, everyday reasons a prescriber might ask for a compounded medication include removing an ingredient a patient is allergic to, adjusting a dose or strength that isn't commercially available, changing the delivery form, for example turning a pill into a liquid or a cream for a patient who can't swallow tablets, or preparing a drug that's in shortage or has been discontinued by its original manufacturer.

The key distinction is that compounding is patient-specific. A compounding pharmacy isn't mass-producing a standardized product for the general market the way a pharmaceutical manufacturer does. It's preparing a customized version of a medication for one patient, based on a prescriber's order, which is also why compounded drugs are regulated differently than manufactured ones.

Two Regulatory Pathways: 503A vs 503B

Compounding in the United States generally happens under one of two sections of the Federal Food, Drug, and Cosmetic Act.

  • Section 503A covers traditional pharmacy compounding. It's tied to an individual patient's valid prescription and is carried out by a licensed pharmacy or physician. This is the pathway most relevant to peptides, and it's the focus of this article.
  • Section 503B covers outsourcing facilities. These can compound in larger batches without a patient-specific prescription on file for each preparation, but they operate under a different, and generally stricter, set of FDA requirements than 503A pharmacies.

Both pathways exist to serve real clinical needs, but they're governed by different rules. Since the current conversation around research peptides centers on individual-patient prescribing, the rest of this article focuses on 503A. For a step-by-step look at getting a compounded peptide prescription, see How to Get Peptides Legally.

The Three Conditions for Legal Compounding Under 503A

For a compounding pharmacy to legally prepare a substance under Section 503A, that substance generally has to meet one of three conditions:

  1. It appears on the FDA's 503A Bulk Drug Substances List, sometimes called the 503A Bulks List.
  2. It has its own official USP or NF monograph, meaning it's already recognized in the U.S. Pharmacopoeia or National Formulary with established quality standards.
  3. It's a component of an already FDA-approved drug.

This is exactly why the 503A Bulks List matters so much for peptides. Most of the research peptides discussed online, including BPC-157, TB-500, and MOTS-c, don't have a USP or NF monograph and aren't a component of an FDA-approved drug. That leaves the Bulks List as the realistic path for any of them to become legally compoundable. For a deeper look at how that list works and how substances get added to it, see What Is FDA's 503A Bulks List?

Where Research Peptides Stand Today

As of this writing, none of the commonly discussed research peptides, including BPC-157, TB-500, MOTS-c, KPV, Semax, Epithalon, CJC-1295, Ipamorelin, Selank, or DSIP, are on the 503A Bulks List. Under the statute alone, that means a compounding pharmacy could not prepare any of them under Section 503A. Since October 28, 2026, however, a draft HHS enforcement discretion policy lets licensed 503A pharmacies compound six of them, BPC-157, TB-500, MOTS-c, KPV, Semax and Epithalon, by prescription under strict conditions. CJC-1295, Ipamorelin, Selank and DSIP are not covered.

On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend six of these peptides, BPC-157, KPV, TB-500, MOTS-c, Semax, and Epithalon, for future inclusion on the 503A Bulks List. That's a meaningful development, but it's important to be precise about what it is: a nonbinding recommendation, not a final rule. The FDA still has to decide whether, and how, to act on it. For the full breakdown of that vote and what would still need to happen for it to translate into an actual rule change, see What Changed With BPC-157, TB-500 and MOTS-c in 2026?

Worth knowing: a PCAC recommendation doesn't change what's legal today. Until the FDA formally adds a substance to the 503A Bulks List, through its own rulemaking process, compounding it under Section 503A remains outside the current framework.

For a running, substance-by-substance view of where individual peptides stand, see the FDA Peptide Status Tracker, and for the broader legal landscape peptides sit in more generally, see Are Peptides Legal in 2026?

Compounded Peptide vs. Research Chemical

It's worth drawing a clear line between two things that get talked about as if they're interchangeable, because they aren't.

A compounded peptide, if and when this becomes legally possible for a given substance, would require an individual patient's valid prescription from a licensed prescriber, prepared by a licensed compounding pharmacy, under FDA and state pharmacy board oversight. It would be a customized medical product tied to one patient's documented need.

A research-chemical peptide bought online and labeled "for research use only" is fundamentally different. It involves no prescription, no patient-specific customization by a pharmacist, and no pharmacy licensing oversight. It exists in a separate regulatory category entirely from a compounded drug. For a closer look at what that "research use only" label actually means and doesn't mean, see What Does "Research Use Only" Mean?

Frequently Asked Questions

What is a compounded medication?

A compounded medication is one that a licensed pharmacist or physician customizes for an individual patient, rather than a drug produced in bulk by a manufacturer. Common reasons include removing an allergen the patient can't tolerate, adjusting a dose or strength a manufacturer doesn't offer, changing the delivery form, such as from a pill to a liquid, or preparing a drug that's in shortage or has been discontinued. Pharmacy compounding is a long-standing, legitimate practice, but it is regulated differently from mass drug manufacturing.

Can a pharmacy compound BPC-157 today?

Yes, with a prescription and under strict conditions. BPC-157 still does not meet the three standard 503A conditions: it is not on the 503A Bulks List, has no USP or NF monograph, and is not part of an FDA-approved drug. But under a draft HHS enforcement discretion policy announced October 28, 2026, licensed 503A pharmacies may compound BPC-157, TB-500, MOTS-c, KPV, Semax and Epithalon for individual patients while FDA completes rulemaking. CJC-1295, Ipamorelin, Selank and DSIP are not covered.

What's the difference between 503A and 503B compounding?

Section 503A covers traditional pharmacy compounding, where a licensed pharmacy or physician prepares a medication tied to an individual patient's valid prescription. Section 503B covers outsourcing facilities, which can compound in larger batches without a patient-specific prescription, under a different and generally stricter set of FDA requirements. Most of the discussion around research peptides centers on 503A, since that's the pathway tied to an individual prescription.

Does the July 2026 FDA vote make peptide compounding legal?

No. On July 23 and 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend six peptides, including BPC-157, TB-500, and MOTS-c, for future inclusion on the 503A Bulks List. That recommendation is nonbinding. FDA has not yet added them to the list through rulemaking, but a draft HHS policy announced October 28, 2026 now lets licensed 503A pharmacies compound those six by prescription, with one peptide per product, a tested ingredient from an FDA-registered manufacturer, set routes of use, a compounded drug label and adverse event reporting. For the full story of that vote, see our dedicated update.

How is a compounded peptide different from a research chemical peptide?

A compounded peptide, where it is legally allowed for a given peptide, would require an individual patient's valid prescription from a licensed prescriber, prepared by a licensed compounding pharmacy, under FDA and state pharmacy board oversight. A research-chemical peptide bought online and labeled 'for research use only' involves none of that: no prescription, no patient-specific customization, and no pharmacy licensing oversight.

Want to see how your own stack lines up? Run it through Rate My Stack, or build one from scratch with the Peptide Protocol Builder.

Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. Regulatory status can change; verify current status directly with the FDA, a licensed pharmacist, or a qualified attorney before making decisions based on this article. As of this writing, none of the research peptides named here are on the Section 503A Bulks List, and none are FDA-approved drugs.